Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

August 11, 2017: By Jon Swedien
Bausch + Lomb Stellaris Elite

Bausch + Lomb Stellaris Elite

Bausch + Lomb has launched the Stellaris Elite vision enhancement system for retinal surgery in the US, the Bridgewater, New Jersey-based company announced Aug. 7.

The Stellaris Elite platform builds on B+L’s Stellaris PC, a dual-function cataract/vitrectomy machine commercialized in 2010. The FDA gave the Stellaris Elite 501(k) clearance in May.

The new system features the ability to seamlessly integrate future technologies, such as the Vitesse hypersonic vitrectomy system, which will be exclusive to the Stellaris Elite, B+L said.

The Vitesse system is the first and only hypersonic, 100 percent open port vitrectomy platform, B+L said.

Stellaris Elite machines configured for retinal surgery will come equipped with the Vitesse technology, while the Vitesse hand-piece is slated to be released commercially in late 2017.

The Stellaris Elite offers a variety of vitrectomy cutters operating up to 7,500 cuts per minute (cpm), B+L said. The system will feature a new 27-gauge BiBlade vitrectomy cutter that offers cut rates up to 15 thousand cpm and features an open-port design resulting in a higher, more consistent flow rate than single port cutters, B+L said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

FDA Warns that Vancomycin Eye Injections May Lead to Blindness

Alcon to Launch Clareon IOL at ESCRS Meeting

Bribery Trial Testimony Focuses on Melgen’s Billing for Lucentis

VSY Biotechnology to Launch AcrivaUD Trinova Trifocal IOL at ESCRS Meeting

Valeant Launches $1 Billion Private Senior Notes Offering

STAAR Surgical Appoints Scott Barnes, MD, as New CMO

Aerie Acquires Envisia Technology for $25M to Advance Retinal Program

Carl Zeiss Meditec Announces Milestone of 1 Million SMILE Procedures

Maryland Team Wins First Phase of NEI Contest to Create Human Retina

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022